RNA
Atrium Therapeutics, Inc.
Nasdaq: RNA · San Diego, CA · Healthcare
$8.20+0.04 (+0.49%)Closed
Market Cap$140.3M
Cash$72.3Mmost recent
Runway7 mo$31.1M Q burn
P/E (TTM)—EPS $-2.15
52-Wk Range$7.61 – $16.54
Avg Volume416.3K3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$8.20-44.4%
Pipeline
Drug candidates sponsored by Atrium Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 1 | ATR 1072 | Cardiac Glycogenosis+3 more | Recruiting | 2028-05 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for RNA. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.